Table of contents

Extended reports

• Attachment to laminin-111 facilitates transforming growth factor β-induced expression of matrix metalloproteinase-3 in synovial fibroblasts (23 November, 2006)

  Maik Hoberg, Maximilian Rudert, Thomas Pap, Gerd Klein, Steffen Gay, Wilhelm K Aicher
• GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice (4 October, 2006)

  C Plater-Zyberk, L A B Joosten, M M A Helsen, J Hepp, P A Baeuerle, W B van den Berg
• Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum (13 October, 2006)

  L Šenolt, D Housa, Z Vernerová, T Jirásek, R Svobodová, D Veigl, K Anderlová, U Müller-Ladner, K Pavelka, M Haluzík
• Reproducibility and sensitivity to change of four scoring methods for the radiological assessment of osteoarthritis of the hand (15 November, 2006)

  Emmanuel Maheu, Christian Cadet, Sylvie Gueneugues, Philippe Ravaud, Maxime Dougados
• Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system (15 November, 2006) Free

  Mikiko Tokunaga, Kazuyoshi Saito, Daisuke Kawabata, Yoshitaka Imura, Takao Fujii, Shingo Nakayamada, Shizuyo Tsujimura, Masao Nawata, Shigeru Iwata, Taeko Azuma, Tsuneyo Mimori, Yoshiya Tanaka
• Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration (17 November, 2006)

  Sophia E Steer, Frances M K Williams, Bernet Kato, Jeffry P Gardner, Paul J Norman, Margaret A Hall, Masayuki Kimura, Robert Vaughan, Abraham Aviv, Tim D Spector
• Sulphasalazine inhibits human antigen-specific immune responses in vivo (19 September, 2006)

  Christina Trollmo, Sveinn Gudmundsson, Nils Feltelius, Siv Rogberg, Göran Smedegård, Lars Klareskog
• Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register (7 November, 2006)

  Tracey M Farragher, Mark Lunt, Diane K Bunn, Alan J Silman, Deborah P M Symmons
• Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate (19 December, 2006)

  J Gratacós, E Casado, J Real, J C Torre-Alonso
• Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial (17 November, 2006) Free

  A Kavanaugh, G G Krueger, A Beutler, C Guzzo, B Zhou, L T Dooley, P J Mease, D D Gladman, K de Vlam, P P Geusens, C Birbara, D G Halter, C Antoni
• Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome (1 November, 2006)

  Daphna Paran, Dan Caspi, David Levartovsky, Ori Elkayam, Ilana Kaufman, Irena Litinsky, Gad Keren, Bella Koifman
• Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? (19 September, 2006)

  A Vannini, K Cheung, M Fusconi, J Stammen-Vogelzangs, J P H Drenth, A C Dall’Aglio, F B Bianchi, L E Bakker-Jonges, W J van Venrooij, G J M Pruijn, A J W Zendman
• Pressure pain thresholds and tender point counts as predictors of new chronic widespread pain in somatising subjects (29 September, 2006)

  A Gupta, J McBeth, G J Macfarlane, R Morriss, C Dickens, D Ray, Y H Chiu, A J Silman
• Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI (26 October, 2006)

  Claudia Schirmer, Alexander K Scheel, Christian E Althoff, Tania Schink, Iris Eshed, Alexander Lembcke, Gerd-Rüdiger Burmester, Marina Backhaus, Bernd Hamm, Kay-Geert A Hermann